218 related articles for article (PubMed ID: 15957978)
1. Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Ponzone R; Sismondi P
Expert Opin Pharmacother; 2005 Jun; 6(7):1257-67. PubMed ID: 15957978
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
3. [Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Aumiller J
MMW Fortschr Med; 2006 Mar; 148(12):4-6, 8. PubMed ID: 16625995
[No Abstract] [Full Text] [Related]
4. Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007.
Montemurro F; Redana S; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2007 Jun; 8(8):1179-88. PubMed ID: 17516881
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
6. Management of breast cancer--Part II.
Turner NC; Jones AL
BMJ; 2008 Jul; 337(7662):a540. PubMed ID: 18621762
[No Abstract] [Full Text] [Related]
7. Controversies in breast cancer: adjuvant and neoadjuvant therapy.
Montemurro F; Redana S; Valabrega G; Aglietta M
Expert Opin Pharmacother; 2005 Jun; 6(7):1055-72. PubMed ID: 15957962
[TBL] [Abstract][Full Text] [Related]
8. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Chen LR
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):218-21. PubMed ID: 20654118
[No Abstract] [Full Text] [Related]
10. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
[TBL] [Abstract][Full Text] [Related]
11. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors--a triumph of translational oncology.
Swain SM
N Engl J Med; 2005 Dec; 353(26):2807-9. PubMed ID: 16382068
[No Abstract] [Full Text] [Related]
13. Advances in breast oncology: the 2002 ASCO meeting.
Singh-Ranger G; Mokbel K;
Curr Med Res Opin; 2002; 18(7):401-6. PubMed ID: 12487506
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer (metastatic).
Stebbing J; Glassman R
Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
[No Abstract] [Full Text] [Related]
15. Anastrozole data show continued delay in relapse, but no clear survival advantage.
Travis K
J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
[No Abstract] [Full Text] [Related]
16. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant treatment of operable breast cancer].
Khosravi Shahi P; Izarzugaza Perón Y; Encinas García S; Díaz Muñoz de la Espada VM; Pérez Manga G
An Med Interna; 2008 Jan; 25(1):36-40. PubMed ID: 18377195
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]